All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ivonescimab Gets Breakthrough Therapy Designation in China for EGFR+ Advanced NSCLC

October 21st 2022

The China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab for use in combination with chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in whom prior treatment with an EGFR TKI has failed.

Nab-sirolimus Under Investigation in TSC1- and TSC2-mutated Gynecologic Cancers and Other Solid Tumors

October 21st 2022

Kathleen N. Moore, MD, MS, discusses the incidence of TSC1 and TSC2 mutations in different gynecologic tumor types, the trial design and eligibility criteria for the PRECISION 1 study, and the importance of genetic testing to identify these mutations and treat them early.

Encorafenib/Binimetinib Delivers Prolonged Survival in BRAF V600–Mutant Melanoma

October 21st 2022

The combination of encorafenib and binimetinib led to sustained improvements in progression-free survival and overall survival, without new safety signals in patients with BRAF V600–mutant melanoma, according to 5-year follow-up of the phase 3 COLUMBUS trial.

Immunotherapy and BRAF-Targeted Therapy Fill Expanded Roles Across Melanoma

October 21st 2022

Immunotherapy and targeted therapy combinations containing BRAF and MEK inhibitors have carved out roles in different settings of melanoma, which has given clinicians different options for treatment sequencing.

Sylvester Pancreatic Cancer Researcher Dr. Nagaraj Nagathihalli Awarded Florida Department of Health Grant

October 21st 2022

The Florida Department of Health has awarded Nagaraj Nagathihalli, PhD, an associate professor at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, a $583,200 grant to study tobacco risk, tumor progression, and therapeutic options for pancreatic cancer.

Mitomycin C Reduces the Number of Procedures Following NMIBC Recurrence

October 21st 2022

Chemoresection with mitomycin C, a nonsurgical treatment modality, significantly reduced the need for transurethral resection of bladder tumors or office biopsy and tumor fulguration following recurrence in patients with recurrent nonmuscle invasive bladder cancer.

Targeting Transcription as a New Frontier in Advanced Pancreatic Cancer

October 21st 2022

A new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.

ctDNA Helps Predict Recurrence in Real-World Analysis of Patients With Resected CRC

October 21st 2022

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer

October 20th 2022

Paul A. DiSilvestro, MD, discussed the pivotal SOLO-1 trial of maintenance olaparib in patients with BRCA-mutated ovarian cancer, updated survival data with the agent in this population, and the next steps for future research.

Immunotherapy-Based Combinations Remain the Focus of Frontline Treatment in Metastatic RCC

October 20th 2022

Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.

Florida Cancer Specialists & Research Institute Chief Medical Officer Shares Spotlight With Global Innovators in Genomic Health

October 20th 2022

Lucio Gordan, MD, chief medical officer of Therapeutics & Analytics for Florida Cancer Specialists & Research Institute, is a featured speaker at the Illumina Genomics Forum in San Diego.

Inroads to Targeting HER2-Mutant Lung Cancer Begin Taking Shape

October 20th 2022

Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.

E-selectin Inhibitor Uproleselan May Bolster SOC Efficacy in AML

October 20th 2022

Richard M. Stone, MD, highlights how uproleselan disrupts E-selectin in the AML tumor microenvironment, the variety of AML regimens that uproleselan may amplify in efficacy, including chemotherapies and venetoclax combinations, and the need for further research to determine whether minimal residual disease negativity rates will improve patient prognoses.

Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma

October 20th 2022

Adjuvant treatment with nivolumab resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival over placebo in patients with completely resected stage IIB or IIC melanoma.

Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL

October 20th 2022

Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.

Adjuvant Palbociclib Plus ET Does Not Prolong IDFS Over ET Alone in Stage IIA ER+ Breast Cancer

October 19th 2022

The addition of palbociclib to adjuvant endocrine therapy (ET) failed to improve invasive disease-free survival over ET alone in patients with estrogen receptor–positive, HER2-negative early breast cancer.

FDA Grants Fast Track Designation to TTI-101 for Advanced Hepatocellular Carcinoma

October 19th 2022

The FDA has granted a fast track designation to TTI-101 for the treatment of patients with relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma.

A Newly Identified Genetic Mutation May Be Key to Developing Thymic Cancer Treatment

October 19th 2022

Recent developments in cancers of the thymus, a small organ located in the mediastinum above the heart, have shined a light on a malignancy that only affects about 400 Americans annually.

Rogaratinib Is Noninferior to Chemo in Pretreated FGFR1/3 mRNA+ Locally Advanced or Metastatic Urothelial Carcinoma

October 19th 2022

Rogaratinib induced an objective response rate similar to that of chemotherapy in patients with FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma who have received at least 1 prior platinum-containing chemotherapy.

Fox Chase Cancer Center Welcomes Charnita Zeigler-Johnson

October 19th 2022

Fox Chase Cancer Center is pleased to announce the hiring of Charnita Zeigler-Johnson, PhD, MPH, as Associate Director of Community Outreach and Engagement.